Contingent value rights have become common in biotechnology deals. More than half of all transactions this year include them, according to a Jefferies report in October.
Continue Reading
View comments
Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments.
Published 1 day ago
Nov 6, 2025 at 8:02 PM
Neutral
Auto